|
|
|
2008 PBMI Drug Benefit Conference
Thursday, February 28, 2008 8:00 am – 9:00 am 9:00 am – 9:45 am William Shrank, MD, MSHS, Instructor, Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital Peer-reviewed research continues to document the links between rational cost-sharing strategies and increased patient compliance. Optimal cost sharing approaches for increasing patient adherence with drug regiments will be described, focusing on the role of generic drugs in compliance with maintenance drug therapies. The essential elements of drug information for patient education and prescription labeling will be presented. 9:45 am – 10:30 am Cyndy Nayer, MA, Executive Director, Center for Health Value Innovation Employee health status is not changed by plan design alone. A health care culture must be engendered to realize an optimal ROI from value-based benefit design. Review research findings from organizations ranging in size from 500 to 100,000 employees to develop strategies for building a value-based health care culture. 10:30 am – 11:00 am 11:00 am – Noon Challenges of Managing the Medicare Part D Benefit Emerging Models in Community Pharmacy Implementing Value-based Drug Benefit Plan Designs Noon 12:45 pm – 1:15 pm Afternoon Breakout Sessions 1:15 pm – 2:05 pm HR Perspectives: Shannon Kampa, PharmD, Senior Associate, Mercer Providing drug benefits to employees and retirees is a complex and costly process. Discuss the major approaches used by employers today including integrated programs (with broker, managed care organization, or third-party administrator) or carve-out programs with a pharmacy benefit manager. Compare and contrast the benefits of each approach by reviewing case study examples of each approach. Industry Trends: Timothy Colligan, RPh, MS, Pharmacy Director, SummaCare The Medicare Modernization Act created a mandate for medication therapy management (MTM) in Part D benefit offerings. The marketplace has responded with a multitude of MTM programs ranging from high tech services delivered via claims adjudication systems to high touch solutions that encompass face-to-face pharmacist consults and polypharmacy case management. Panel members will discuss this continuum and the evolution of MTM. Managed Care Pharmacy Perspectives: Bridget Eber, PharmD, Towers Perrin Reference-based pricing makes good economic sense for your drug benefit program. Determine critical communication strategies to implement a program effectively. Evaluate desired clinical and economic outcomes from this approach, often referred to as a therapeutic MAC (maximum allowable cost) program. ACPE #027-999-08-002-L04-P. Learning objectives. 2:05 pm – 2:15 pm 2:15 pm – 3:05 pm Keith D. Bruhnsen, MSW, Assistant Director Benefit Office and Manager Prescription Drug Plan, Pharmacy benefit manager (PBM) and plan sponsor relationships are often challenged by the competing interests of PBM profitability and plan sponsor cost containment. Employer and union trust fund case studies will illustrate how developing a collaborative relationship with a transparent PBM fosters greater control, plan flexibility, and utilization management. Both case studies demonstrate how a “carve-out” approach offers significant advantages in cost savings and quality improvements. The University of Michigan and the Teamsters Rx have both achieved substantial savings and will share their experience, operational processes and lessons learned. Industry Trends: Maria Sciame, PharmD, Director of Clinical Services, PMSI Pharmacy utilization management in Workers’ Compensation populations is a challenge in an arena mired in state-specific regulation. Discuss formulary strategies that facilitate cost containment while maintaining quality patient care standards. Describe clinical programs that target appropriate and effective use of medication therapies to contain costs and mitigate risk. Managed Care Pharmacy Perspectives: Kimberly McDonough, PharmD, President, Advanced Pharmacy Concepts New standards in the practice of pharmacy are emerging. Identify how Pharmacy Quality Alliance metrics to monitor patient safety are being implemented. Discuss the value of improved patient safety to your drug benefit program. ACPE #027-999-08-003-L05-P. Learning objectives. 3:05 pm – 3:20 pm 3:20 pm – 4:10 pm Kristin M. Dossey, Senior Benefits Analyst, Salt River Project Arizona’s Salt River Project (SRP) is the nation’s third-largest public power and water utility. SRP provides benefits to 4,800 employees and 1,900 retirees. Identify drug cost savings for employers, focusing on the importance of driving utilization to lowest net cost drug medically appropriate for a patient. Describe the impact of this lowest net cost strategy on Medicare Part D Retiree Drug Subsidy reconciliation. Industry Trends:
Comparing PBM Pricing Models Robert I. Garis, PhD, Assistant Professor of Pharmaceutical and Administrative Sciences, Creighton University
Lisa Gish, MS, RN, Executive Director, Tri-State Business Group on Health
PBMs use varying pricing models for their services, ranging from traditional to fully transparent approaches. Quantitative analysis facilitates detailed comparisons of these different pricing models. The Tri-State Business Group on Health will share how it is integrating quantitative analysis into its PBM selection and management processes.
Managed Care Pharmacy Perspectives: Ed Pezalla, MD, National Medical Director, Aetna Pharmacy Despite rising costs, managing specialty drug therapies effectively is critical for a positive return on investment. This session explains optimal processes for providing needed support services for specialty drug therapies. Different pharmacy dispensing channels for these high cost drugs will be compared and contrasted. Clinical programs designed to optimize patient outcomes will be presented. ACPE #027-999-08-004-L04-P. Learning objectives. 4:10 pm – 4:20 pm 4:20 pm – 5:10 pm Michael Brady, Employee Benefits Director, City of Milwaukee Effectively managing drug spend through transparent pay-for-performance products, such as Drug Utilization Review (DUR) programs, is risk free to the plan sponsor. Learn how the City of Milwaukee reached its savings and health management objectives through successful execution of this clinical program. Industry Trends: Richard Johnson, Consultant, The Segal Company The Governmental Accounting Standards Board (GASB) statements 43 and 45 about other post-employment benefits (OPEB) liabilities have far-reaching impact on the financial statements of public sector employers. As public employers comply with GASB 43 and 45 that govern the funding of retiree health care and drug benefits, plan designs may change. Review case study examples of how some public entities may change drug benefit plan designs to minimize OPEB liabilities. Managed Care Pharmacy Perspectives: Patrick P. Gleason, PharmD, Director of Outcomes Assessment, Prime Therapeutics Current trends have led to an increase in value-based pharmacy management. Integrating medical and pharmacy claims from these value-based programs creates opportunities to use risk stratification to improve outcomes and control costs. The selection and use of clinical programs based on risk stratification to improve health outcomes will be discussed. ACPE #027-999-08-001-L04-P. Learning objectives. 5:10 pm – 7:00 pm Wednesday, February 27 I Friday, February 29
|
Copyright 2007 Pharmacy Benefit Management Institute, LP